| SCHEDULE OF SEGMENT INFORMATION |
SCHEDULE
OF SEGMENT INFORMATION
Goodwill
and Assets
| | |
NanoVibronix | | |
ENvue | | |
Corporate | | |
Total | |
| Balance sheet at June 30, 2026 | |
| | | |
| | | |
| | | |
| | |
| Goodwill | |
$ | - | | |
$ | 29,082 | | |
$ | - | | |
$ | 29,082 | |
| Assets | |
$ | 2,206 | | |
$ | 36,199 | | |
$ | - | | |
$ | 38,405 | |
| | |
| | | |
| | | |
| | | |
| | |
| Balance sheet at December 31, 2025 | |
| | | |
| | | |
| | | |
| | |
| Goodwill | |
$ | - | | |
$ | 29,082 | | |
$ | - | | |
$ | 29,082 | |
| Assets | |
$ | 1,924 | | |
$ | 39,200 | | |
$ | - | | |
$ | 41,124 | |
Segment
operating results
| Six Months Ended June 30, 2026: | |
NanoVibronix | | |
ENvue | | |
Corporate | | |
Total | |
| Revenues | |
$ | 589 | | |
$ | 303 | | |
$ | - | | |
$ | 892 | |
| Cost of revenues | |
| 466 | | |
| 747 | | |
| - | | |
| 1,213 | |
| Research and development | |
| 319 | | |
| 705 | | |
| - | | |
| 1,024 | |
| Selling and marketing | |
| 775 | | |
| 1,149 | | |
| - | | |
| 1,924 | |
| General and administrative | |
| 467 | | |
| 971 | | |
| 4,478 | | |
| 5,916 | |
| Total operating loss | |
$ | (1,438 | ) | |
$ | (3,269 | ) | |
$ | (4,478 | ) | |
$ | (9,185 | ) |
| Six Months Ended June 30, 2025: | |
NanoVibronix | | |
ENvue | | |
Corporate | | |
Total | |
| Revenues | |
$ | 1,367 | | |
$ | 152 | | |
$ | - | | |
$ | 1,519 | |
| Cost of revenues | |
| 875 | | |
| 310 | | |
| - | | |
| 1,185 | |
| Research and development | |
| 1,184 | | |
| 383 | | |
| - | | |
| 1,567 | |
| Selling and marketing | |
| 325 | | |
| 676 | | |
| - | | |
| 1,001 | |
| General and administrative | |
| 1,231 | | |
| 802 | | |
| 1,561 | | |
| 3,594 | |
| Total operating loss | |
$ | (2,248 | ) | |
$ | (2,019 | ) | |
$ | (1,561 | ) | |
$ | (5,828 | ) |
| Three Months Ended June 30, 2026: | |
NanoVibronix | | |
ENvue | | |
Corporate | | |
Total | |
| Revenues | |
$ | 55 | | |
$ | 184 | | |
$ | - | | |
$ | 239 | |
| Cost of revenues | |
| 77 | | |
| 428 | | |
| - | | |
| 505 | |
| Research and development | |
| 279 | | |
| 231 | | |
| - | | |
| 510 | |
| Selling and marketing | |
| 496 | | |
| 702 | | |
| - | | |
| 1,198 | |
| General and administrative | |
| 87 | | |
| 328 | | |
| 3,085 | | |
| 3,500 | |
| Total operating loss | |
$ | (884 | ) | |
$ | (1,505 | ) | |
$ | (3,085 | ) | |
$ | (5,474 | ) |
ENVUE
MEDICAL, INC.
Notes
to the Interim Condensed Consolidated Financial Statements (Unaudited)
(Amounts
in thousands except share and per share data)
| Three Months Ended June 30, 2025: | |
NanoVibronix | | |
ENvue | | |
Corporate | | |
Total | |
| Revenues | |
$ | 445 | | |
$ | 49 | | |
$ | - | | |
$ | 494 | |
| Cost of revenues | |
| 295 | | |
| 234 | | |
| - | | |
| 529 | |
| Research and development | |
| 772 | | |
| 244 | | |
| - | | |
| 1,016 | |
| Selling and marketing | |
| 180 | | |
| 493 | | |
| - | | |
| 673 | |
| General and administrative | |
| 807 | | |
| 610 | | |
| 835 | | |
| 2,252 | |
| Total operating loss | |
$ | (1,609 | ) | |
$ | (1,532 | ) | |
$ | (835 | ) | |
$ | (3,976 | ) |
|